HONG KONG SAR – Media OutReach<\/a>
\u00a0<\/span><\/p>\n
As a subsidiary of Jacobson
\u00a0<\/p>\n
Further to the successful listing, <\/span>the Group will aim at
\u00a0<\/p>\n
Leveraging the Group’s
\u00a0<\/p>\n
The net proceeds from the Public Offer amounted to approximately HK$10.6
HONG KONG SAR – Media OutReach
– 5 February 2021 – JBM (Healthcare)
Limited (“JBM Healthcare” or “Company“, together with its
subsidiaries, the “Group”), a Hong
Kong-based company that markets and distributes branded healthcare products
across Greater China, Southeast Asia and certain other countries, started trading
today on the Main Board of The Stock Exchange …<\/p>\n","protected":false},"author":1,"featured_media":11994,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/11993"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=11993"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/11993\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media\/11994"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=11993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=11993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=11993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n– 5 February 2021 – JBM (Healthcare)
\nLimited<\/a><\/b> (“JBM Healthcare<\/b>” or “Company<\/b>“, together with its
\nsubsidiaries, the “Group”)<\/b>, a Hong
\nKong-based company that markets and distributes branded healthcare products
\nacross Greater China, Southeast Asia and certain other countries, started trading
\ntoday on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”)
\nunder stock code 2161.<\/span><\/p>\n![](\"https:\/\/release.media-outreach.com\/release.php\/Images\/Thumb\/500x0\/123040\/JBM-Healthcare-image.jpg#image-123040\")
<\/span><\/p>\nJBM Healthcare’s diversified brand portfolio comprises a total of 20 principal brands, including 11 third-party brands and 9 own brands.<\/h5>\n
\n
<\/p>\n
\n
<\/p>\n
\nPharma Corporation Limited<\/b> (“Jacobson Pharma”; Stock Code: 2633), JBM
\nHealthcare is a unique field player with drug expertise and ethical heritage
\nthat prioritises product efficacy and quality to meet consumers’ healthcare
\nneeds. As a leading healthcare brand operator in Hong Kong, the Group carried a
\ntotal of 20 principal brands, including 11 third-party brands and 9 own brands covering
\nboth OTC proprietary medicines and OTC proprietary Chinese medicines. Upon completion of the public listing, Jacobson
\nPharma continues to indirectly hold over 50% equity interest in JBM Healthcare
\nand JBM Healthcare remains as a subsidiary of Jacobson Pharma. <\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nexpanding its product offerings and deepening product penetration in China
\nthrough cross-border e-commerce initiatives as a result of the rapid growth of
\nthe PRC cross-border e-commerce market, as well as the rising demand for
\noverseas healthcare products along with an increasingly structured and formalized
\ncross-border e-commerce channel in the PRC market. Simultaneously, the Group will
\nalso further expand its portfolio through organic growth and mergers and
\nacquisitions to maintain its competitive position and ensure its future growth
\nand success. <\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nestablished local business relationships and networks, JBM Healthcare targets
\nto develop a branded healthcare product sourcing and distribution platform in
\nAsia through the integration of its regional resources and foothold, strengthening
\nand expanding its geographical reach in Southeast Asia. In addition, backed by its
\nextensive market base in Hong Kong, the Group is well poised to unleash the
\nsales and distribution potential of its Chinese medicine practitioner network. <\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nmillion. The Group will allocate 47.2% of the proceeds <\/span>to fund portfolio development and brand management of proprietary Chinese
\nmedicines; while 43.4% will be used to pay for the obtaining of additional
\ndistribution rights from third-party brand owners, as part of the strategy to
\ngrow its third-party brand product portfolio. The remaining 9.4 % will be used
\nto supplement working capital and for general corporate purposes.<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"